0001192482-20-000119.txt : 20200205 0001192482-20-000119.hdr.sgml : 20200205 20200205162000 ACCESSION NUMBER: 0001192482-20-000119 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200203 FILED AS OF DATE: 20200205 DATE AS OF CHANGE: 20200205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRANO JOSEPH J JR CENTRAL INDEX KEY: 0001304755 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35112 FILM NUMBER: 20579000 MAIL ADDRESS: STREET 1: C/O MEDGENICS, INC. STREET 2: 435 DEVON PARK DRIVE BLDG 700 CITY: WAYNE STATE: PA ZIP: 19087 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aevi Genomic Medicine, Inc. CENTRAL INDEX KEY: 0001138776 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 980217544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 435 DEVON PARK DRIVE, STREET 2: SUITE 715 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 610-254-4201 MAIL ADDRESS: STREET 1: 435 DEVON PARK DRIVE, STREET 2: SUITE 715 CITY: WAYNE STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: MEDGENICS, INC. DATE OF NAME CHANGE: 20090623 FORMER COMPANY: FORMER CONFORMED NAME: MEDGENICS INC DATE OF NAME CHANGE: 20010419 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2020-02-03 1 0001138776 Aevi Genomic Medicine, Inc. GNMX 0001304755 GRANO JOSEPH J JR C/O AEVI GENOMIC MEDICINE, INC. 435 DEVON PARK DRIVE, SUITE 715 WAYNE PA 19087 1 0 0 0 Common Stock 2020-02-03 4 D 0 75683 D 0 D Common Stock 2020-02-03 4 D 0 27000 D 0 I By wife Common Stock 2020-02-03 4 D 0 56780 D 0 I By The Grano Children's Trust Robert Silver and Joseph C Grano Trustees Common Stock 2020-02-03 4 D 0 15384 D 0 I By The Garano Family Foundation Stock Option (Right to Purchase) 6.50 2020-02-03 4 D 0 15000 0 D 2024-01-02 Common Stock 15000 0 D Stock Option (Right to Purchase) 7.01 2020-02-03 4 D 0 20000 0 D 2025-02-18 Common Stock 20000 0 D Stock Option (Right to Purchase) 1.32 2020-02-03 4 D 0 20000 0 D 2027-06-22 Common Stock 20000 0 D Stock Option (Right to Purchase) 1.55 2020-02-03 4 D 0 50000 0 D 2028-04-17 Common Stock 50000 0 D Stock Option (Right to Purchase) 4.83 2020-02-03 4 D 0 20000 0 D 2026-04-15 Common Stock 20000 0 D Warrant (Right to Buy) 2.84 2020-02-03 4 D 0 7061 0 D 2022-10-17 Common Stock 7061 0 D Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock. This option which became exercisable on January 2, 2015, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. This option which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. This option which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. This option which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. This option which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void. /s/ Joseph J. Grano, Jr. 2020-02-05